If You Invested in Kiromic Biopharma Inc (KRBP)

Kiromic BioPharma, Inc. (OTCQB: KRBP) is a clinical-stage, fully integrated biotherapeutics company focused on immuno-oncology. According to the company’s public statements, Kiromic is developing a multi-indication allogeneic cell therapy platform that uses the natural potency of gamma delta T-cells (GDT cells) to target solid tumors. The company reports that it uses its proprietary DIAMOND® artificial intelligence (AI) 2.0 target discovery engine to identify novel targets for cell therapies. Kiromic maintains offices in Houston, Texas and its common stock trades on the OTCQB under the symbol KRBP.

Business focus and therapeutic platform

Kiromic describes itself as a clinical-stage company developing cell therapies for patients with advanced cancers. Its work centers on allogeneic, off-the-shelf gamma delta T-cell therapies. Allogeneic products, as described by the company, consist of unmodified, donor-derived gamma delta T cells that are manufactured for use in multiple patients rather than being derived from each individual patient.

The company’s lead product candidate is Deltacel™ (KB-GDT-01), which Kiromic identifies as the leading candidate in its GDT platform. Deltacel is described as an investigational gamma delta T-cell therapy designed to exploit the natural potency of GDT cells to target solid cancers, with an initial clinical focus on stage 4 metastatic or locally advanced non-small cell lung cancer (NSCLC) that has failed to respond to standard therapies. Kiromic cites preclinical studies in which Deltacel combined with low-dose radiation demonstrated a favorable safety and efficacy profile.

Deltacel-01 Phase 1 clinical trial

Kiromic is conducting an open-label Phase 1 clinical trial titled “Phase 1 Trial Evaluating the Safety and Tolerability of Gamma Delta T Cell Infusions in Combination With Low Dose Radiotherapy in Subjects With Stage 4 Metastatic Non-Small Cell Lung Cancer” (NCT06069570). In this study, patients with advanced NSCLC who have failed to respond to standard therapies receive intravenous infusions of Deltacel™ combined with courses of low-dose, localized radiation over a defined treatment period.

The company states that the primary objective of the Deltacel-01 trial is to evaluate safety and tolerability. Secondary measurements include objective response, progression-free survival (PFS), overall survival, time to progression, time to treatment response and disease control rates. Kiromic has reported interim clinical observations such as partial responses, tumor volume reductions, stable disease, and progression-free survival durations in individual patients enrolled in the trial, as well as the absence of dose-limiting toxicities in early cohorts, based on data from its press releases.

Regulatory designations and clinical sites

Kiromic has announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to Deltacel™ (KB-GDT-01) in combination with low-dose radiation therapy for the treatment of patients with metastatic NSCLC who have progressed on at least two lines of standard-of-care therapy, including platinum-based chemotherapy, immune checkpoint inhibitors and targeted therapy, with the goal of improving progression-free survival and overall survival. The company indicates that Deltacel is being evaluated in the Deltacel-01 Phase 1 study in patients with stage 4 NSCLC who have failed to respond to standard therapies.

Kiromic has also reported the activation of multiple clinical trial sites for Deltacel-01. These include the Beverly Hills Cancer Center, Clinical Research Advisors Koreatown (a satellite location of Beverly Hills Cancer Center), Texas Oncology in Tyler, Texas, Virginia Oncology Associates in Norfolk, Virginia, and the University of Arizona Cancer Center (UACC), which Kiromic notes is one of the NCI-Designated Comprehensive Cancer Centers in the United States. The company has described the progression of the trial into an expansion phase following a unanimous recommendation from the Deltacel-01 Safety Monitoring Committee after review of safety data from initial cohorts.

Use of DIAMOND® AI 2.0 platform

In its public communications, Kiromic states that it uses its proprietary DIAMOND® artificial intelligence (AI) 2.0 target discovery engine to discover novel targets for immuno-oncology and to develop and commercialize cell therapies. The company describes DIAMOND AI as a platform where data science meets target identification, with the stated aim of compressing the time and resources required to develop a live drug. This AI-driven approach is positioned by Kiromic as central to its strategy of building a multi-indication allogeneic cell therapy platform.

Historical and legacy focus

Earlier descriptions of Kiromic’s activities, such as the Polygon summary, reference a focus on cancer-associated biomarkers and small molecules, the development of clinical diagnostic tools for rapid detection of cancer-associated antigens, and the design of personalized, cancer-specific targeted immunotherapy strategies. These descriptions emphasize the company’s interest in both diagnostic and therapeutic applications aimed at earlier diagnosis, accurate monitoring of treatment response, and potentially improved patient outcomes. More recent company press releases emphasize the clinical-stage development of Deltacel and the gamma delta T-cell platform, indicating a strong focus on cell therapy-based immuno-oncology.

Industry classification and sector

Based on the provided classification, Kiromic operates within Research and Development in Biotechnology under the broader sector of Professional, Scientific, and Technical Services. As a clinical-stage biotherapeutics company, its activities are concentrated on early-stage clinical development, preclinical research, and target discovery in oncology, rather than on commercialized pharmaceutical products.

Stock and regulatory context

Kiromic’s common stock trades on the OTCQB market under the ticker symbol KRBP. The company has publicly disclosed interaction with the U.S. Securities and Exchange Commission (SEC), including a settlement of a previously disclosed SEC investigation related to the non-disclosure by prior executive management of clinical holds placed by the FDA on certain investigational new drug applications. Kiromic has stated that, in light of its self-reporting, remediation and cooperation, the SEC determined not to impose a civil penalty on the company and that there are no ongoing undertakings in connection with that settlement.

Kiromic BioPharma in the context of oncology R&D

Within oncology research and development, Kiromic positions itself as a company focusing on allogeneic gamma delta T-cell therapies for solid tumors, particularly NSCLC. Its public updates emphasize clinical trial progress, safety and efficacy observations in enrolled patients, regulatory designations, and the expansion of trial sites. For investors and observers evaluating KRBP stock, key themes in the company’s disclosures include the advancement of the Deltacel-01 trial, the performance of Deltacel in terms of safety and progression-free survival, the role of DIAMOND AI in target discovery, and the company’s collaborations with cancer centers and clinical research organizations.

Frequently asked questions about Kiromic BioPharma (KRBP)

• What does Kiromic BioPharma do?
  Kiromic BioPharma, Inc. describes itself as a clinical-stage, fully integrated biotherapeutics company developing a multi-indication allogeneic cell therapy platform that exploits the natural potency of gamma delta T-cells to target solid tumors. It focuses on immuno-oncology and uses its proprietary DIAMOND® AI 2.0 platform to discover novel targets.
• What is Deltacel™ (KB-GDT-01)?
  Deltacel™ (KB-GDT-01) is Kiromic’s investigational gamma delta T-cell therapy and the leading candidate in its GDT platform. It is an allogeneic product consisting of unmodified, donor-derived gamma delta T cells and is being evaluated in the Deltacel-01 Phase 1 clinical trial for patients with stage 4 metastatic or locally advanced NSCLC who have failed to respond to standard therapies.
• What is the Deltacel-01 clinical trial?
  Deltacel-01 is an open-label Phase 1 trial titled “Phase 1 Trial Evaluating the Safety and Tolerability of Gamma Delta T Cell Infusions in Combination With Low Dose Radiotherapy in Subjects With Stage 4 Metastatic Non-Small Cell Lung Cancer” (NCT06069570). Patients receive intravenous infusions of Deltacel combined with low-dose, localized radiation. The primary objective is to evaluate safety and tolerability, while secondary endpoints include objective response, progression-free survival, overall survival, time to progression, time to treatment response and disease control rates.
• Which cancer type is Kiromic primarily targeting?
  Kiromic’s initial clinical focus for Deltacel is non-small cell lung cancer (NSCLC), specifically stage 4 metastatic or locally advanced disease in patients who have failed to respond to standard therapies. The company notes that NSCLC represents a substantial proportion of lung cancer cases.
• What is DIAMOND® AI 2.0?
  DIAMOND® AI 2.0 is Kiromic’s proprietary artificial intelligence target discovery engine. The company states that it uses this platform to discover novel targets for immuno-oncology and to support the development and commercialization of cell therapies, aiming to compress the time and resources required to develop a live drug.
• Has Deltacel received any FDA designations?
  Kiromic has announced that the U.S. Food and Drug Administration granted Fast Track designation to Deltacel™ (KB-GDT-01) in combination with low-dose radiation therapy for the treatment of patients with metastatic NSCLC who have progressed on at least two lines of standard-of-care therapy, including platinum-based chemotherapy, immune checkpoint inhibitors and targeted therapy.
• Where is Kiromic BioPharma based?
  The company states that it maintains offices in Houston, Texas. It also partners with multiple clinical sites in different U.S. locations for the Deltacel-01 trial.
• On which market does KRBP trade?
  Kiromic BioPharma’s common stock trades on the OTCQB market under the ticker symbol KRBP.
• What was the SEC investigation mentioned by Kiromic?
  Kiromic has disclosed that it entered into a settlement agreement with the U.S. Securities and Exchange Commission related to the prior non-disclosure of clinical holds placed by the FDA on certain investigational new drug applications. The company reports that, in light of its self-reporting, remediation and cooperation, the SEC did not impose a civil penalty and there are no ongoing undertakings in connection with the settlement.
• How does Kiromic’s historical focus on biomarkers relate to its current activities?
  Earlier descriptions highlight Kiromic’s work on cancer-associated biomarkers, small molecules, and diagnostic tools for rapid detection of cancer-associated antigens, as well as personalized targeted immunotherapy strategies. More recent disclosures emphasize clinical-stage development of allogeneic gamma delta T-cell therapies and the use of DIAMOND AI, indicating an evolution toward cell therapy-based immuno-oncology while remaining within the broader field of oncology research and development.